1. Home
  2. NEOG vs GLPG Comparison

NEOG vs GLPG Comparison

Compare NEOG & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neogen Corporation

NEOG

Neogen Corporation

HOLD

Current Price

$9.24

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$27.73

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEOG
GLPG
Founded
1981
1999
Country
United States
Belgium
Employees
N/A
452
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
NEOG
GLPG
Price
$9.24
$27.73
Analyst Decision
Buy
Buy
Analyst Count
4
2
Target Price
$10.67
$36.50
AVG Volume (30 Days)
2.5M
118.1K
Earning Date
04-09-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$894,661,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$459.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.53
$24.74
52 Week High
$11.43
$37.78

Technical Indicators

Market Signals
Indicator
NEOG
GLPG
Relative Strength Index (RSI) 46.73 36.68
Support Level $8.98 $27.73
Resistance Level $10.12 $34.04
Average True Range (ATR) 0.36 0.56
MACD -0.01 0.08
Stochastic Oscillator 26.02 26.20

Price Performance

Historical Comparison
NEOG
GLPG

About NEOG Neogen Corporation

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: